Trial Profile
Phase I/II study of oral administration of S 49076 given in combination with gefitinib in patients with EGFR mutated advanced non-small-cell lung cancer who have progressed after treatment with EGFR tyrosine kinase inhibitor.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Jul 2021
Price :
$35
*
At a glance
- Drugs S-49076 (Primary) ; Gefitinib
- Indications Adenocarcinoma; Adenosquamous carcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors IRIS; Servier
- 03 Apr 2019 Results of molecular profiling of T790M-negative NSCLC patients progressing on EGFR-TKI, presented at the 110th Annual Meeting of the American Association for Cancer Research
- 28 Nov 2018 This trial has been Discontinued in Spain (End date: 2018-11-07).
- 08 Aug 2018 This trial has been completed in Hungary.